BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2014 7:02:00 PM | Browse: 1506 | Download: 2251
 |
Received |
|
2014-08-09 21:00 |
|
Peer-Review Started |
|
2014-08-11 08:37 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-08-30 15:14 |
|
Revised |
|
2014-09-10 01:57 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-11-10 15:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-11-10 16:00 |
|
Articles in Press |
|
2014-11-10 16:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-11-28 15:50 |
|
Publish the Manuscript Online |
|
2014-12-13 19:01 |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Review |
| Article Title |
Incretin-based therapies in prediabetes: Current evidence and future perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Georgios S Papaetis |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Georgios S Papaetis, MD, PhD, Internal Medicine and Diabetes Clinic, Eleftherios Venizelos Avenue 62, Paphos 8049, Cyprus. gpapaetis@yahoo.gr
|
| Key Words |
Type 2 diabetes; Prediabetes; Impaired fasting glucose; Impaired glucose tolerance; Glucagon-like peptide-1; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists |
| Core Tip |
The beneficial effects of incretin-based therapies on β-cell function in patients with type 2 diabetes (T2D) suggested their possible use in individuals with prediabetes, when greater β-cell mass and function are preserved. Both dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated improvements on β-cell function both in preclinical studies and short-term clinical studies. Until future date for their safety are available, large, long term, prevention trials will be required in order to determine whether they can stabilize or reverse β-cell loss and promote a sustained reduction in the development of T2D in this population.
|
| Publish Date |
2014-12-13 19:01 |
| Citation |
Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-834 |
| URL |
http://www.wjgnet.com/1948-9358/full/v5/i6/817.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v5.i6.817 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
